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a b s t r a c t
Genetic variants surrounding the interferon-λ3 (IFNL3) gene are strongly associated with clearance of
hepatitis C virus (HCV). A variant (rs368234815 TT/ΔG) upstream of IFNL3 was recently implicated to
control expression of a novel gene termed IFNL4. We conducted genetic analysis of rs368234815 in a
chronic HCV patient cohort and molecular studies of IFNL4 in primary human hepatocytes (PHHs).
Analysis of PHHs that are heterozygous at rs368234815 revealed that the IFNL4 transcript isoform is rare,
accounting for 2% of transcripts arising from the IFNL4 locus. Nevertheless, IFNL4 over-expression
inhibited replication of multiple Flaviviridae and IFNL4 anti-viral potency required the IFNL receptor. In
contrast to IFNL3, IFNL4 was inefﬁciently secreted and appeared to act in a cell-autonomous manner.
Genetic analysis revealed associations of rs368234815 with sustained virological response and pre-
treatment viral load. The ﬁndings suggest that IFNL4 is an atypical IFNL whose activity may be
maladaptive to clearance of HCV infection.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Human genetic variation impacts susceptibility to infectious
diseases. This is particularly true for hepatitis C virus (HCV), a
member of the Flaviviridae and a major world-wide cause of liver
disease (Thomas, 2013). Multiple genome-wide association studies
(GWAS) have identiﬁed polymorphisms near the interferon-λ3
(IFNL3; formerly IL28B) gene that predict efﬁcacy of pegylated IFN-
α/ribavirin combination therapy for chronic infection and sponta-
neous HCV clearance during the acute phase of infection (Ge et al.,
2009; Suppiah et al., 2009; Tanaka et al., 2009; Thomas et al.,
2009). The most strongly associated single nucleotide polymorph-
isms (SNPs) found in GWAS (known as discovery SNPs) were
rs12979860 in European-Americans and African-Americans, and
rs8099917 in East Asians. The former is located upstream of IFNL3
and confers 42-fold likelihood of sustained virological response
(SVR) between favorable and non-favorable alleles. These SNPs are
unlikely to be responsible for improved clearance themselves
because they are distally located from known functional elements,
such as promoter binding sites or open reading frames. Rather,
these variants likely co-segregate with other polymorphisms that
exert biological functions related to IFNL expression or activity.
IFNL3 is a member of the type III IFNs, whose genes are clustered
together on chromosome 19 (Kotenko et al., 2003; Sheppard et al.,
2003). The IFNLs bind a distinct receptor complex that is expressed on
epithelial cells (Sommereyns et al., 2008). Receptor binding initiates
JAK-STAT signal transduction, leading to expression of interferon-
stimulated genes that confer an anti-viral state. Notably, IFNLs inhibit
HCV replication in vitro (Marcello et al., 2006; Robek et al., 2005) and
IFNL3 genotype has been linked to liver interferon-stimulated gene
mRNA expression (Honda et al., 2010; Urban et al., 2010).
Recently, RNA sequencing of primary human hepatocytes
(PHHs) treated with polyinosinic:cytidylic acid (poly I:C, a mimic
of dsRNA) revealed transcriptional activity upstream of the IFNL3
gene (Prokunina-Olsson et al., 2013). Many of the identiﬁed
transcript isoforms contain putative open reading frames (ORFs).
One transcript encoding a 179 amino acid (p179) protein exhibited
antiviral activity against a non-infectious HCV replicon when
overexpressed and was named IFNL4. Of note, the rs12979860
discovery SNP lies within the ﬁrst intron of IFNL4 (Fig. 1A). A
dinucleotide variant in this region (rs368234815 TT/ΔG) causes a
frame shift on these ORFs and may alter translation of IFNL4mRNA
(Prokunina-Olsson et al., 2013). A direct role for IFNL4 in HCV
clearance is presently unclear, and whether the IFNL4 protein is
endogenously produced in human hepatocytes infected with HCV
is uncertain due to lack of Western blot or proteomic data.
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Here, we examined the expression of IFNL4 transcripts in PHHs
and human cell lines, characterized IFNL4 secretion and require-
ment for the IFNL receptor, and performed genetic analysis of
rs368234815 in a large well-characterized chronic HCV cohort.
While the exact role of IFNL4 in control of HCV infection is still
elusive, the molecular and genetic evidence suggest that
rs368234815 is likely relevant to viral clearance in patients
infected with HCV.
Methods
Genotyping and statistical analysis
DNA from the IDEAL cohort (McHutchison et al., 2009) was used for genotyping.
Taqman genotyping design for rs368234815 is: forward primer 50-TGGGTCCTGT-
GCACGGTGAT-30 , reverse primer 50-TCCCTCAGCGCCTTGGCA-30 , and probe 50-CGCAG
(AA/C)GGCCCCCCGG-30 . Taqman genotyping was performed according to the protocol
suggested by the manufacturer (Life Technologies). Genotypes for rs12979860 were
obtained from the Illumina Human610-Quad genotyping array as described previously
(Ge et al., 2009). Logistic regression and linear regression were performed in STATA
(StataCorp) and R (www.r-project.org). Clinical phenotypes [SVR, rapid virological
response (RVR), and pre-treatment viral load] were used as a dependent variable, and
genetic polymorphisms (rs12979860 and rs368234815) were used as independent
variables as indicated in the tables for both logistic and linear regression models. All P
values and 95% conﬁdence intervals (CI) reported were calculated from two-tailed
distributions. In multiple logistic or linear regression analyses, both rs12979860 and
rs368234815 were considered as independent variables to assess independent associa-
tions after accounting for the effect of each other.
Cell culture, transfection, and virus infections
Huh7.5 (Blight et al., 2002) and A549 cells were cultured in high glucose DMEM
supplemented with 10% heat-inactivated FBS and non-essential amino acids. A2EN
cells stably transduced with ISRE-luciferase (Vignola et al., 2010) were kindly
provided by Raphael Valdivia (Duke University) and grown in keratinocyte serum-
free medium (Invitrogen) supplemented with 30 μg/mL recombinant EGF, 0.1 ng/mL
bovine pituitary extract and 0.4 mM CaCl2. For evaluation of IFNL antiviral potency
Fig. 1. IFNL4 is anti-viral against infectious Flaviviridae. (A) Relative positions of IFNL3 and IFNL4mRNAs are indicated along with locations of genetic variants relevant to this
study. Proteins produced by IFNL4 transcripts are indicated for the rs368234815 ΔG genotype. (B) Huh7.5 cells transiently transfected with the indicated expression plasmids
were infected with HCV, DENV2, or YFV-17D and rates of infection were measured by quantitative immunoﬂuorescence using antibodies against viral antigens. All data are
shown as mean7S.D. (C) Representative immunoﬂuorescence images that illustrate levels of virus infection after transfection with the indicated plasmids are shown.
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and STAT1 phosphorylation, Huh7.5 cells were transfected with the indicated CMV
promoter-driven expression plasmids in 24-well plates using 0.8 μg DNA and 2 μl
Lipofectamine 2000 per well unless otherwise indicated. The next day, cells were re-
fed media and infected with either HCV JFH1 (Kato et al., 2001), DENV-2 New Guinea
C, or YFV 17D. HCV infections were performed at a multiplicity of infection (MOI) of
0.1 whereas ﬂavivirus infections were carried out using an MOI of 1. At 24
(ﬂaviviruses) or 72 (HCV) hours after infection, cells were ﬁxed in cold methanol
and stained with either 4G2 anti-envelope (ﬂaviviruses) or C7-50 anti-core (HCV)
antibodies as described (Kato et al., 2006). Rates of infection were determined using
a Cellomics ArrayScan high content imager. Infectious HCV in cell supernatants were
determined by TCID50 assay (Lindenbach, 2009). All reported infection experiments
were performed at least three separate times and each experiment had three
replicates per condition. Representative experiments are shown in Figs. 1–4.
For evaluation of IFNL activity in cell supernatants, Huh7.5 were transfected as
described above and re-fed with supplemented DMEM 4 h after transfection. 48 h
later, cell supernatants were harvested, clariﬁed by centrifugation, and used to treat
naïve cells. Subsequently, cell lysates were isolated 6 h after treatment for STAT1
Western blotting, or infected with YFV 24 h after treatment and rates of virus
infection determined 24 h post-infection as described above.
For knockdown of IFNLR1, siRNA duplexes were obtained from Qiagen and used
to transfect Huh7.5 cells with RNAiMAX (Invitrogen) at a ﬁnal concentration of
30 nM. Cells were re-fed with media 24 h later and transfected with IFNL
expression plasmids as described above. Cells were then infected with YFV 24 h
after plasmids transfection and rates of infection determined as described above.
PHH experiments and RT-PCR
Cryopreserved (lot #: Hu8122) or freshly isolated PHHs (lot #: Hu8171) were
obtained from Life Technologies. Cells in 24-well plates were maintained in
William's E medium supplemented with the Maintenance Supplement Pack,
Serum-free (Life Technologies) 37 1C overnight for recovery. The next day, cells
were transfected with 5 μg of poly I:C (Sigma) and 6.4 μl Lipofectamine 2000 per
well as described previously (Park et al., 2012). Total RNA was extracted by RNeasy
mini column (Qiagen) and treated with on-column DNase to eliminate genomic
DNA carry-over. Reverse transcription with random primers (Life Technologies) was
subsequently performed to obtain cDNA. Forward primer 50-GTCCT GTGCA CGGTG
ATC-30 and reverse primer 50-GATAA CTGGC AATAA ATTTA AACCG GG-30 were used
to generate pooled PCR products from cDNA transcribed from the IFNL4 genomic
region. pCRs-Blunt II-TOPOs was used for blunt end insertion of PCR products.
Bacterial colonies were randomly picked for sequencing to determine isoform and
genotype.
For studies of endogenous IFNL4 mRNAs in A549 cells, conﬂuent monolayers in
24-well dishes were transfected with 1.6 µg poly I:C and 4 μl of lipofectamine 2000
per well. Four hours post-transfection, total RNA was isolated with Trizol reagent
and then subjected to reverse transcription using a gene speciﬁc reverse primer
(50-TCTTT GATAA CTGGC AATAA-30). PCR was subsequently performed with this
and a forward primer (50-GTCCT GTGCA CGGTG ATC-30.
Western blotting, cloning, and RT-qPCR
Cells were lysed using RIPA buffer and subjected to SDS-PAGE and Western
blotting. Antibodies to total STAT1 and phospho-STAT1(Tyr 701) were obtained
from Cell Signaling Technology. Antibody to polypyrimidine tract-binding protein
was kindly provided by M.A. Garcia-Blanco (Duke University). For analysis of cell
culture supernatants by Western blot, proteins were concentrated by precipitation
with trichloroacetic acid and resuspended in sample buffer prior to fractionation by
SDS-PAGE.
Fig. 2. IFNL4 inhibits production of infectious HCV and induces STAT1 phosphor-
ylation after over-expression. (A) Huh7.5 cells were transfected with the indicated
plasmids as in Fig. 1 and infected with HCV. Supernanants were collected at 72 h
post-infection and titered by TCID50 assay. (B) Western blot analysis of STAT1,
STAT1-PO4 and polypyrimidine tract-binding protein (PTB) is shown from cells
transfected with the indicated plasmids for 18 h. Quantiﬁcation of STAT1- PO4
signals normalized to PTB is shown below the STAT1- PO4 blot.
Fig. 3. IFNL4 is not functionally secreted. (A) Huh7.5 cells were transfected with the
indicated plasmids and supernatants harvested 48 h p.t. Naïve cells were infected
with YFV-17D 24 h after treatment with the respective supernatants and levels of
virus infection determined 24 h later by quantitative immunoﬂuorescence.
(B) Supernatants generated after plasmid transfection were used to treat A2EN
cells that stably harbor a luciferase transgene under control of an ISRE element.
(C) Conditioned media from cells expressing the indicated proteins were used to
treat naïve cells for 4 h and the same factors were analyzed by Western blot as
in Fig. 2. Quantiﬁcation of STAT1- PO4 signals normalized to PTB is shown below
the STAT1- PO4 blot.
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IFNL4 and p131 cDNA expression constructs encoding Halo tags were kindly
provided by L. Prokunina-Olsson (NCI). For generation of IFNL3 expression constructs,
the IFNL3 ORF (AY184374.1) encoding a C-terminal Flag tag was synthesized (Integrated
DNA Technologies) and inserted into pcDNA5/FRT/TO (Invitrogen) using KpnI and NotI
restriction sites. A comparable IFNL4 expression construct was similarly established
(Prokunina-Olsson et al., 2013). Knockdown of IFNLR1 mRNA expression was deter-
mined by RT-qPCR. Brieﬂy, Huh7.5 cells transfected in triplicate with siRNA duplexes
(see above) were harvested 48 h post-transfection for RNA isolation (RNeasy, Qiagen)
and cDNA synthesis using the High Capacity cDNA synthesis kit (Applied Biosystems).
Subsequently, qPCR was performed using Power SYBR green master mix (Applied
Biosystems) to measure IFNLR1 transcript levels using forward primer 50-GGATC TGAAG
TATGA GGTGG C-30 and reverse primer 50-GTAGA TGGTT CTGGC ACTGA G-30 . Levels of
β-2-microglobulin mRNA were analyzed for calibration using forward primer 50-TGTCT
GGGTT TCATC CATCC GACA-30 and reverse primer 50-TCACA CGGCA GGCAT ACTCA
TCTT-30 .
Results
IFNL4 exhibits broad antiviral activity
The dinucleotide variant rs368234815 (TT/ΔG) near the discovery
SNP (rs12979860) has been proposed to inﬂuence HCV clearance
through the production of IFNL4 in subjects carrying the ΔG allele
(Fig. 1A). To expand on these ﬁndings, we investigated the effects of
IFNL4 over-expression on replication of several infectious Flaviviridae
species in Huh7.5 human hepatoma cells (Blight et al., 2002): HCV
(JFH-1 strain), dengue virus serotype 2 (DENV2; New Guinea C strain),
and the yellow fever virus vaccine (YFV; 17D strain). Transfection of
vector plasmid, a construct encoding an inactive isoform of IFNL4
(p131; Fig. 1A), and an IFNL3 expression plasmid served as controls.
Replication of each virus was similarly inhibited by expression of IFNL3
and IFNL4 compared to the vector alone and to inactive p131 as
measured by immunoﬂuorescence staining for viral antigen followed
by quantitative imaging (Fig. 1B and C). The effects of IFNL3 or IFNL4
plasmids were similar over a range of concentrations (Supplementary
Fig. 1A), suggesting that the two IFNLs have similar potencies when
expressed transiently. Measurements of infectious HCV in super-
natants of transfected cells revealed an approximate 10-fold reduction
in infectious particles due to either IFNL3 or IFNL4 over expression
(Fig. 2A). In addition, STAT1 phosphorylation levels were similar in
lysates from cells transfected with either IFNL expression construct
(Fig. 2B). These observations conﬁrm the antiviral potency of IFNL4
when exogenously expressed by plasmid transfection.
IFNL4 anti-viral activity is cell autonomous
IFNs are typically secreted molecules and trigger paracrine and
autocrine signal transduction pathways leading to expression of
interferon-stimulated genes (ISGs) that produce an anti-viral pheno-
type (Schoggins and Rice 2011; Schneider et al., 2014). Recombinant
IFNL4 was previously described to lack biological activity for unknown
reasons (Prokunina-Olsson et al., 2013). To test whether IFNL4 is
functionally secreted from cells, Huh7.5 cells were transfected with
expression plasmids as described in Fig. 1 and supernatants were
harvested 48 h post-transfection. Subsequently, naïve Huh7.5 cells
were treated with supernatants and then infected with YFV to assay
for anti-viral effects. The IFNL3-containing supernatant clearly antag-
onized YFV infection, as expected. In contrast, IFNL4 supernatant
lacked detectable antiviral activity (Fig. 3A). We also utilized a stable
cell line harboring ﬁreﬂy luciferase under control of an interferon-
sensitive response element (ISRE) to analyze supernatants from
transfected cells. Whereas supernatant from cells transfected with
the IFNL3 plasmid triggered signal transduction to the ISRE promoter
at the lowest dose utilized, the supernatants from cells that express
IFNL4 did not produce a response (Fig. 3B). Similarly, IFNL3-containing
supernatant strongly induced STAT1 phosphorylation in treated cells
compared to supernatant from IFNL4-transfected cells (Fig. 3C).
We further analyzed IFNL4 secretion by Western blot analysis.
Huh7.5 cells were transfected with plasmids encoding either ﬂag-
tagged IFNL4, halo-tagged IFNL4, or halo-tagged p131. After 48 h,
equivalent fractions of cell lysates and supernatants were subjected to
SDS-PAGE and Western blotting using IFNL4 antibody. Each protein
was abundantly expressed in cell lysates and migrated as multiple
bands of different apparent molecular weight (Supplementary Fig. 2),
possibly reﬂecting post-translational glycosylation (Hamming et al.,
2013). In contrast, each protein was barely detectable in supernatant
samples, conﬁrming that IFNL4 and p131 are inefﬁciently secreted.
Together, these data suggest that IFNL4 is an atypical anti-viral factor
that does not require secretion for activity in vitro.
The antiviral activity of IFNL4 requires IFNLR1 expression
To be classiﬁed as a type III interferon, IFNL4 should functionally
require IFNLR1, the class II cytokine receptor that, along with IL10Rβ,
transduces signals for all λ-interferons (Kotenko et al., 2003). To
determine whether IFNL4 activity requires IFNLR1, we inhibited
expression of IFNLR1 in Huh7.5 cells using three independent siRNAs
and then expressed p131, IFNL3, or IFNL4 proteins in these cells.
Knockdown of IFNLR1 mRNA levels was veriﬁed by RT-qPCR due to
lack of reliable antibodies for the IFNLR1 protein (Supplementary
Fig. 1B). Cells were then infected with YFV to assess anti-viral
phenotypes. Transfection of cells with each of the three siRNAs negated
the antiviral effects of both IFNL3 and IFNL4 (Fig. 4). These results
indicate that IFNLR1expression is required for IFNL4 biological activity.
Endogenous IFNL4 mRNA isoforms are expressed in lung epithelial
carcinoma cells
No known immortalized human cell lines are known to express
IFNL4. We stimulated multiple cell lines (A549, Huh7, HepG2 and
Huh7.5) by transfection with poly I:C and performed RT-PCR with
pan-amplifying IFNL4 primers. Only A549 carcinoma cells
Fig. 4. IFNL4 anti-viral activity requires the IFNL receptor. Non-silencing (NS) and three individual IFNLR1 siRNAs were introduced into Huh7.5 cells followed by transfection
with the indicated expression plasmids. Subsequently, cells were infected with YFV-17D to evaluate cellular antiviral phenotype. All data show mean values7S.D. Asterisks
(**) indicate P values ofr0.005 as calculated by unpaired Student's t-test.
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expressed IFNL4 transcripts, each of which contained a novel
intron located upstream of the start codon. Speciﬁcally, three
transcripts were identiﬁed, the most abundant of which corre-
sponded to mRNA isoforms predicted to express p107 and p131
proteins in the context of the rs368234815 ΔG genotype (Fig. 5).
These mRNA isoforms were also the most abundant transcripts
identiﬁed in PHHs (see below). The third transcript contained
novel splice sites and does not correspond to previously reported
IFNL4mRNAs. These observations suggest that A549 cells may be a
tractable model for studies of IFNL4 alternative pre-mRNA splicing
and transcriptional regulation.
IFNL4 is weakly expressed in primary human hepatocytes
IFNL4 is predicted to be synthesized only by the rs368234815 ΔG
allele through alternative splicing (Fig. 1A). We evaluated the relative
frequency of IFNL4 mRNA transcripts in primary human hepatocytes
(PHHs) from two rs368234815 heterozygous donors stimulated by
transfection of poly I:C. We sequenced individual clones derived from
RT-PCR ampliﬁcation using primers designed to hybridize to all
known IFNL4 mRNA isoforms. Sanger sequence analysis of 105
individual clones revealed similar ratios of mRNA isoforms between
the two donors (Supplementary Table 1). Approximately 72% of
transcripts were derived from the beneﬁcial rs368234815 TT allele
(Table 1). This was surprising, as most of these transcripts are
predicted targets of nonsense mediated decay (NMD) due to the
presence of an in-frame stop codon located upstream of exon
junctions. Out of 46 and 59 clones analyzed for each PHH donor,
respectively, only 2 were identiﬁed in a single donor that encoded
functional IFNL4. This suggests that, in the context of rs368234815
heterozygosity, a large majority (98%) of spliced mRNA transcripts
arising from the IFNL4 locus do not produce functional IFNL4 protein.
rs368234815 is highly correlated with the discovery SNP
(rs12979860) and exhibits stronger statistical association with pre-
treatment viral load than rs12979860
To further investigate the association of IFNL4 with clinical
phenotypes, we genotyped and analyzed the rs368234815 and
rs12979860 variants in the IDEAL Cohort (McHutchison et al., 2009),
a large well-characterized sample of patients chronically-infected with
HCV (n¼794 European-American; n¼171 African-American). Linkage
disequilibrium (LD) analysis revealed that rs368234815 is strongly
associated with rs12979860 in European-American patients
(r2¼0.977), with somewhat lower LD in African-American patients
(r2¼0.713). We performed association tests of both rs12979860 and
rs368234815 with patient phenotypes (SVR, RVR, and pre-treatment
viral load) using a logistic regression or linear regression model to
evaluate the correlation of each polymorphism with clinical features.
The rs12979860 CC genotype was previously associated with a 2 fold
higher chance of achieving SVR compared to that of combined non-CC
genotypes (CT and TT), and the CT genotype only showed slightly
higher SVR than the TT homozygous patients (Ge et al., 2009),
suggesting a mixture between additive and recessive genetic models.
Therefore, we performed regression analyses with both recessive and
additive models separately (Table 2 and Supplementary Table 2). In
the recessive model (rs12979860 CC versus non-CC, and rs368234815
TT/TT versus non-TT/TT), the associations of rs12979860 and
rs368234815 with SVR were highly signiﬁcant in both populations
(Table 2). However, because genetic variants surrounding IFNL3 and
IFNL4 are in high linkage disequilibrium (inherited together as a
linkage disequilibrium block), most polymorphisms in this region
exhibit strong association with these clinical phenotypes. In order to
question whether rs368234815 shows independent association when
controlled for the discovery SNP (rs12979860), which would support a
causal role for rs368234815, we performedmultiple logistic regression
analysis. After correcting for the effect of rs12979860, the P value for
rs368234815 remained signiﬁcant in both populations for SVR
(P¼0.039 in European-Americans and 0.042 in African-Americans),
suggesting stronger association of rs368234815 with SVR than the
discovery SNP (Table 2). However, the P values of both populations
were driven by a small number of patients that have disparate
genotype between rs12979860 and rs368234815 and are also of
borderline signiﬁcance (cutoff¼0.05). In the additive model,
rs368234815 no longer showed statistical signiﬁcance after correcting
for rs12979860 (Supplementary Table 2). Therefore, the genetic
evidence for whether rs368234815 is directly causal with respect to
SVR is still insufﬁcient and merits further investigation.
We previously observed that viral load is signiﬁcantly correlated
with rs12979860 genotype such that patients with the C allele have
higher pre-treatment viral load (1.5-fold; P¼1.21 1010) (Ge
et al., 2009). Since rs368234815 has lower LD (r2¼0.713) with the
discovery SNP in African-Americans compared with Caucasians
(r2¼0.977), there is a higher frequency of disparate genotypes and
therefore greater resolution to identify independent effects of
rs368234815 and rs12979860. We found that in African-American
patients, both rs12979860 and rs368234815 are associated with
pre-treatment viral load (P¼1.00 103 for rs12979860 and 2.99
105 for rs368234815). After correcting for the discovery SNP
Fig. 5. Expression of IFNL4 mRNA isoforms in A549 cells. Cells were either mock-treated or transfected with poly I:C and total RNA isolated 4 h post-transfection for RT-PCR
detection of IFNL4. Identiﬁed transcripts and corresponding predicted proteins based on rs368234815 genotype are depicted on the right.
Table 1
IFNL4 mRNA isoforms expressed in stimulated PHHs from two donors.
Transcript Genotype Amino acids Count Subject to NMD Frequency (%)
p131 TT 75 19 Yes 18.1
ΔG 131 12 No 11.4
p179 TT 123 24 Yes 22.9
ΔG 179 2 No 1.9
p170 TT 124 10 No 9.5
ΔG 170 1 No 1.0
p107 TT 51 11 Yes 10.5
ΔG 107 9 No 8.6
Others TT – 12 – 11.4
ΔG – 5 – 4.8
Total TT 76 72
ΔG 29 28
Sum 105 100.0
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(rs12979860) in the multiple linear regression analysis, rs368234815
showed independent association with pre-treatment viral load
(P¼0.012; Table 2). The independent association of rs368234815 with
pre-treatment viral load was also evident in multiple linear regression
analysis using an additive genetic model (P¼0.042 after correcting for
rs12979860; Supplementary Table 2). Taken together, these observa-
tions suggest that IFNL4 expression may inﬂuence pre-treatment viral
load in HCV-infected patients.
Discussion
Multiple genome-wide association studies have identiﬁed
polymorphisms near the IFNL3 gene that predict HCV clearance,
but the functional genetic variant(s) contributing to this effect
phenotype have been elusive (Ge et al., 2009; Suppiah et al., 2009;
Tanaka et al., 2009; Thomas et al., 2009). Here, we analyzed the
genetic associations and functional effects of rs368234815. Our
in vitro assays clearly indicated that IFNL4 exhibits antiviral
potency against multiple members of the Flaviviridae when over-
expressed by plasmid transfection in cultured human hepatoma
cells. IFNL4 potency also requires the cognate IFNLR1 that is
utilized by other IFNL cytokines, and is therefore accurately
classiﬁed as a member of the IFNL family. An important feature
of IFNL4 appears to be its relatively inefﬁcient secretion, suggest-
ing that autocrine signaling through binding to IFNLR1 may occur
in the context of endosomes. In agreement with our observations,
Hamming et al. (2013) recently reported that over-expressed IFNL4
is not efﬁciently secreted and requires IFNLR1 for anti-viral activity.
Together, these ﬁndings establish that IFNL4 is a newly identiﬁed
type III IFN that is functional if expressed to sufﬁcient levels.
We observed that in rs368234815 heterozygous PHHs, IFNL4
mRNAs transcribed from the rs368234815 ΔG allele are not
abundantly expressed, compared to TT allele mRNAs which are
predicted to be degraded by NMD. This observation was unex-
pected, and suggests that endogenous IFNL4 mRNA isoforms may
be poorly translated, because NMD requires cytoplasmic
translation (Chang et al., 2007), and/or that genetic variation
surrounding IFNL4 differentially regulates the transcription of
IFNL4 isoforms based on genotype. Moreover, the observation that
only 2% of mRNA transcripts arising from IFNL4 loci in hetero-
zygous primary cells encode the active IFNL4 protein may explain
the difﬁculty of detecting endogenous IFNL4 by traditional Wes-
tern blot procedures (data not shown). IFNL4 mRNA isoforms that
would produce inactive proteins (p107 and p131) were relatively
abundant in the analyzed PHH cultures and we observed a similar
trend in cultured A549 cells where only transcripts excluding the
IFNL4-speciﬁc exon were detectable. These observations suggest
that alternative splicing of IFNL4 pre-mRNA could signiﬁcantly
regulate production of IFNL4 protein and subsequent anti-viral
responses. It will be of interest to investigate whether common
genetic variants may inﬂuence IFNL4 splicing or transcription.
Our ﬁndings and those of other groups present an apparent
paradox: IFNL4 exhibits clear anti-viral activity in vitro yet its potential
for expression is correlated with poor outcome of HCV infection.
While this is seemingly incongruous, we suggest that two features of
IFNL4 may contribute to its potential maladaptive role in HCV control.
First, IFNL4 does not appear to be strongly expressed in primary cells.
Second, IFNL4 is not efﬁciently secreted in vitro and is predicted to act
in an autocrine manner in the liver. Based on these observations, it is
possible that HCV infection triggers weak hepatic IFNL4 expression
that is ineffective at halting productive infection, yet induces a state of
refractoriness to secreted IFNL3 and IFN-α. In agreement with this
scenario, multiple studies have documented elevated basal ISG
expression in livers of patients who respond poorly to IFN-based
therapy (Urban et al., 2010; Dill et al., 2011; Kurosaki et al., 2011;
Sarasin-Filipowicz et al., 2008; Sheahan et al., 2014) and it is possible
that this is driven by expression of IFNL4 in patients with rs368-
234815 ΔG.
McFarland et al. recently reported that IFNL3 mRNA may be
targeted by muscle-speciﬁc miRNAs whose expression is somehow
triggered by HCV replication. Moreover, a 30 untranslated region SNP
(rs4803217 G/T) appears to alter miRNA-mRNA seed base-pairing
Table 2
Association of candidate causal variants with clinical phenotypes by a recessive genetic model.
European-American (N¼794)
LD (r2)¼0.977 Logistic regression Linear regression
SVR RVR Viral load
OR (95% CI)* P OR (95% CI)* P coefﬁcient (95% CI) P
rs12979860 (C/C vs non-C/C) 7.10 (5.04–10.01) 5.111029 7.88 (4.88–12.71) 2.911017 14.69 (7.82–21.55) 2.97105
rs368234815 (TT/TT vs non-TT/TT) 7.42 (5.24–10.50) 1.311029 7.53 (4.69–12.07) 5.761017 15.06 (8.19–21.92) 1.92105
Multiple logistic regression Multiple linear regression
rs12979860(correcting for rs368234815) 0.65 (0.06–6.47) 0.71 10.21 (0.97–106.92) 0.053 9.07 (56.25–38.1) 0.706
rs368234815(correcting for rs12979860) 11.44 (1.13–115.46) 0.039 0.77 (0.075–7.89) 0.825 24.04 (23.19–71.27) 0.318
African-American (N¼171)**
LD (r2)¼0.713 Logistic regression Linear regression
SVR RVR Viral load
OR (95% CI)* P OR (95% CI)* P coefﬁcient (95% CI) P
rs12979860 (CC vs non-CC) 5.70 (2.36–13.74) 1.08104 6.19 (1.17–32.73) 0.032 28.80 (12.07–45.51) 0.001
rs368234815 (TT/TT vs non-TT/TT) 8.04 (3.10–20.81) 1.79105 3.47 (0.60–20.28) 0.167 37.53 (20.26–54.81) 2.99105
Multiple logistic regression Multiple linear regression
rs12979860 (correcting for rs368234815) 1.34 (0.24–7.44) 0.74 11.02 (0.98–124.06) 0.052 3.32 (33.27–26.63) 0.827
rs368234815 (correcting for rs12979860) 6.23 (1.06–36.48) 0.042 0.45 (0.03–5.97) 0.548 40.46 (8.93–71.98) 0.012
LD is pairwise linkage disequilibrium between rs12979860 and rs368234815.
n Odds ratio (95% conﬁdence interval).
nn In African-Americans, N¼157 in RVR.
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leading to a small (30%) increase in IFNL3 expression for the
rs4803217 G allele due to escape from miRNA regulation (McFarland
et al., 2014). The actual contribution of rs4803217 to HCV clearance is
not clear and this variant has not yet been genotyped for association
with SVR in a cohort of HCV patients. However, rs368234815ΔG and
rs4803217 T are in high LD (r2¼0.966 in European-Americans, 0.701
in African-Americans). Thus, individuals with HCV-induced IFNL4
expression would be predicted to express less IFNL3 in hepatocytes
due to post-transcriptional regulation by rs4803217, potentially
exacerbating the maladaptive effects of IFNL4 expression.
The association between rs368234815 and pre-treatment viral
load in the IDEAL cohort is consistent with previously reported
ﬁndings that rs368234815 is signiﬁcantly better correlated with
normalized viral load decrease during treatment than the
rs12979860 discovery SNP (Prokunina-Olsson et al., 2013). These
ﬁndings are also consistent with a recent report describing a positive
correlation between liver IFNL4 mRNA and HCV RNA levels
(Amanzada et al., 2013). However, although the IDEAL cohort is one
of the largest and best characterized HCV cohorts available, there is
presently not enough statistical evidence for stronger association of
rs368234815 with SVR than the discovery SNP in this cohort. Despite
this, rs368234815 has been reported to be signiﬁcantly more pre-
dictive of SVR than rs12979860 in a Swiss cohort of chronically-
infected patients (Bibert et al., 2013). However, in the Swiss cohort, the
reported LD between rs12979860 and rs368234815 is r2¼0.91, which
is lower than the LD reported in this study (r2¼0.977). This dis-
crepancy may be explained by differences in population structure
between the two cohorts, although both cohorts are composed of self-
reported Caucasians. The extremely high LD in the Caucasian popula-
tion in the IDEAL cohort may also limit the statistical power to
distinguish the independent association of the two variants.
In summary, we explored rs368234815 as a candidate causal
variant underlying the GWAS association for HCV clearance using
diverse experimental approaches. However, a deﬁnitive causal role for
rs368234815 in determining HCV clearance (SVR) is still uncertain and
merits further investigation, including demonstration of endogenous
IFNL4 protein by Western blot and/or proteomic methods.
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